MCID: PLM039
MIFTS: 42

Pulmonary Neuroendocrine Tumor malady

Categories: Cancer diseases, Respiratory diseases, Neuronal diseases

Aliases & Classifications for Pulmonary Neuroendocrine Tumor

Aliases & Descriptions for Pulmonary Neuroendocrine Tumor:

Name: Pulmonary Neuroendocrine Tumor 12 14
Neuroendocrine Neoplasm of Lung 69

Classifications:



External Ids:

Disease Ontology 12 DOID:5410
NCIt 47 C5670
SNOMED-CT 64 707594002
UMLS 69 C1334452

Summaries for Pulmonary Neuroendocrine Tumor

MalaCards based summary : Pulmonary Neuroendocrine Tumor, also known as neuroendocrine neoplasm of lung, is related to neuroendocrine tumor and peroneal nerve paralysis. An important gene associated with Pulmonary Neuroendocrine Tumor is DLL3 (Delta Like Canonical Notch Ligand 3), and among its related pathways/superpathways are Neuroscience and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Paclitaxel and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include lung, thyroid and lymph node, and related phenotypes are behavior/neurological and growth/size/body region

Wikipedia : 71 Pulmonary neuroendocrine tumors are neuroendocrine tumors localized to the lung: bronchus or pulmonary... more...

Related Diseases for Pulmonary Neuroendocrine Tumor

Diseases related to Pulmonary Neuroendocrine Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 73)
id Related Disease Score Top Affiliating Genes
1 neuroendocrine tumor 10.3
2 peroneal nerve paralysis 10.3 CHGA SYP
3 thymus small cell carcinoma 10.3 CHGA SYP
4 brain stem ependymoma 10.2 CHGA SYP
5 perineural angioma 10.2 CALCA CHGA SYP
6 uterine corpus sarcoma 10.2 NCAM1 RET
7 extrahepatic biliary papillomatosis 10.2 CHGA SYP
8 non specific chronic endometritis 10.2 CHGA NCAM1 SYP
9 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 6 10.2 CHGA NEUROD1
10 testicular trophoblastic tumor 10.2 CALCA CHGA SYP
11 main bronchus cancer 10.2 CHGA NCAM1 SYP
12 superior vena cava syndrome 10.2 CHGA NCAM1 SYP
13 fragile x-associated tremor/ataxia syndrome 10.2 CHGA NCAM1 SYP
14 anal squamous cell carcinoma 10.2 CHGA NCAM1 SYP
15 gastric duplication cysts 10.2 CHGA SOX2 SYP
16 aneurysm 10.2 CALCA CHGA RET
17 myoepithelial carcinoma 10.2 CHGA NCAM1 SYP
18 parathyroid carcinoma 10.2 CALCA CHGA RET
19 acinar cell cystadenocarcinoma 10.2 CHGA SOX2 SYP
20 peeling skin syndrome 10.2 CHGA NCAM1 SYP
21 intrahepatic bile duct adenoma 10.2 NCAM1 SYP
22 childhood teratocarcinoma of the testis 10.2 CALCA CHGA RET
23 prolactin producing pituitary tumor 10.1 CHGA SYP
24 sternum lymphoma 10.1 CDH2 CHGA NCAM1 SYP
25 cardioauditory syndrome of sanchez cascos 10.1 CALCA CHGA GHRH SYP
26 t-cell adult acute lymphocytic leukemia 10.1 CHGA RET SYP
27 hypoparathyroidism-intellectual disability-dysmorphism syndrome 10.1 NCAM1 RET SYP
28 villous adenocarcinoma 10.1 CHGA NKX2-1 SYP
29 spasmodic dysphonia 10.1 CHGA NKX2-1 SYP
30 glomus tumor 10.1 NCAM1 SYP
31 zollinger-ellison syndrome 10.1 CHGA RET SYP
32 cavernous hemangioma of face 10.1 CHGA NKX2-1 SYP
33 exudative glomerulonephritis 10.1 CHGA NKX2-1 SYP
34 epithelioid malignant peripheral nerve sheath tumor 10.1 CHGA SYP
35 mitochondrial complex ii deficiency 10.1 CHGA NKX2-1 SYP
36 bone marrow cancer 10.1 CHGA NKX2-1 SYP
37 hunter macpherson syndrome 10.1 CHGA NKX2-1 SYP
38 gastrinoma 10.1 CALCA NKX2-1 RET
39 cowden syndrome 3 10.1 CALCA CHGA RET SYP
40 vestibular gland benign neoplasm 10.1 CHGA RET SYP
41 benign shuddering attacks 10.1 CALCA CHGA RET SYP
42 leukemia, acute promyelocytic, somatic 10.1 CHGA GHRH RET
43 peritoneal serous papillary adenocarcinoma 10.0 CALCA NKX2-1 RET
44 tooth agenesis, selective, 5 10.0 ASCL1 NCAM1 RET SYP
45 brachial plexus neuropathy 10.0 CHGA NCAM1 NKX2-1 SYP
46 oral leukoedema 10.0 CHGA NCAM1 NKX2-1 SYP
47 meige syndrome 10.0 CHGA NCAM1 NKX2-1 SYP
48 atopic dermatitis 10.0 NKX2-1 SOX2 SYP
49 pheochromocytoma 10.0 ASCL1 CALCA CHGA RET SYP
50 muscular dystrophy-dystroglycanopathy , type a, 10 10.0 CALCA CHGA NKX2-1 RET

Graphical network of the top 20 diseases related to Pulmonary Neuroendocrine Tumor:



Diseases related to Pulmonary Neuroendocrine Tumor

Symptoms & Phenotypes for Pulmonary Neuroendocrine Tumor

MGI Mouse Phenotypes related to Pulmonary Neuroendocrine Tumor:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.27 SLC2A1 SOX2 SRC SYP ASCL1 CHL1
2 growth/size/body region MP:0005378 10.2 ASCL1 CDH2 CHGA CHL1 DLL3 ERCC1
3 cellular MP:0005384 10.17 ASCL1 CDH2 ERCC1 NCAM1 NEUROD1 NKX2-1
4 endocrine/exocrine gland MP:0005379 10.07 ASCL1 CHGA ERCC1 GHRH NEUROD1 NFIB
5 homeostasis/metabolism MP:0005376 10.03 CDH2 CHGA ERCC1 GHRH NEUROD1 NFIB
6 embryo MP:0005380 10.01 CDH2 DLL3 ERCC1 RET SLC2A1 SOX2
7 mortality/aging MP:0010768 10 TJP1 CHGA DLL3 ERCC1 NCAM1 NEUROD1
8 nervous system MP:0003631 9.86 SLC2A1 SOX2 SRC SYP TJP1 ASCL1
9 respiratory system MP:0005388 9.23 ASCL1 CHL1 NEUROD1 NFIB NKX2-1 RET

Drugs & Therapeutics for Pulmonary Neuroendocrine Tumor

Drugs for Pulmonary Neuroendocrine Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 249)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 4,Phase 1,Phase 2 33069-62-4 36314
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22916-47-8 4189
3
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2 159351-69-6 6442177
4
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53123-88-9 5284616 6436030 46835353
5
Carboplatin Approved Phase 4,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
6 pancreatic polypeptide Phase 4,Phase 2,Phase 3,Phase 1
7 Albumin-Bound Paclitaxel Phase 4,Phase 1,Phase 2
8 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2
9 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
10 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
11 Antifungal Agents Phase 4,Phase 3,Phase 1,Phase 2
12 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
13 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 1,Phase 2
14 Antimitotic Agents Phase 4,Phase 1,Phase 2
15 Antineoplastic Agents, Phytogenic Phase 4,Phase 1,Phase 2
16
Oxaliplatin Approved, Investigational Phase 2, Phase 3 61825-94-3 5310940 9887054 6857599, 9887054 43805
17
Tranexamic Acid Approved Phase 3 1197-18-8 5526
18
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
19
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
20
Levoleucovorin Approved Phase 2, Phase 3 68538-85-2
21
Doxorubicin Approved, Investigational Phase 3,Phase 1,Phase 2 23214-92-8 31703
22
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
23
Octreotide Approved, Investigational Phase 3,Phase 2,Phase 1 83150-76-9 383414 6400441
24
Ifosfamide Approved Phase 3 3778-73-2 3690
25
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
26
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
27
nivolumab Approved Phase 3,Phase 1,Phase 2 946414-94-4
28
Somatostatin Approved Phase 3,Phase 1,Phase 2,Early Phase 1 38916-34-6, 51110-01-1 53481605
29
lanreotide Approved Phase 3,Phase 2,Early Phase 1 108736-35-2
30
Dabrafenib Approved Phase 3,Phase 2 44462760 44516822
31
Trametinib Approved Phase 3,Phase 2 871700-17-3 11707110
32
leucovorin Approved, Nutraceutical Phase 2, Phase 3 58-05-9 54575, 6560146 143
33
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
34
Doxil Approved June 1999 Phase 3,Phase 1,Phase 2 31703
35 Interleukin-2 Phase 3,Phase 1,Phase 2
36 Analgesics Phase 3,Phase 1,Phase 2
37 Coagulants Phase 3
38 Hemostatics Phase 3
39 Analgesics, Non-Narcotic Phase 3,Phase 1,Phase 2
40 Vaccines Phase 3,Phase 1,Phase 2
41 Peripheral Nervous System Agents Phase 3,Phase 1,Phase 2
42 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
43 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
44 Immunoglobulins Phase 3,Phase 1,Phase 2
45 Antibodies, Monoclonal Phase 3,Phase 1,Phase 2
46 Antifibrinolytic Agents Phase 3
47 Antimetabolites Phase 2, Phase 3,Phase 1
48 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
49 Antibodies Phase 3,Phase 1,Phase 2
50 Alkylating Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 233)
id Name Status NCT ID Phase
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4
3 Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors Completed NCT01595009 Phase 4
4 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3
5 The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis Unknown status NCT01496196 Phase 3
6 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3
7 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
8 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
9 Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors Recruiting NCT02683941 Phase 3
10 ImmuniCell® in Patients With Advanced Cancers Recruiting NCT02459067 Phase 2, Phase 3
11 Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Recruiting NCT02224781 Phase 3
12 Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) Active, not recruiting NCT01524783 Phase 3
13 M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma Not yet recruiting NCT00477906 Phase 3
14 Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors Terminated NCT01755182 Phase 3
15 Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor Unknown status NCT01175096 Phase 1, Phase 2
16 Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours Unknown status NCT00323076 Phase 1, Phase 2
17 A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma Unknown status NCT01065805 Phase 1, Phase 2
18 Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors Unknown status NCT00178698 Phase 2
19 Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients Unknown status NCT01134250 Phase 1, Phase 2
20 Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA) Unknown status NCT01584115 Phase 1, Phase 2
21 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
22 Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors Completed NCT00002470 Phase 2
23 KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors Completed NCT02250885 Phase 2
24 Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer Completed NCT01173523 Phase 2
25 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2
26 Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma Completed NCT00093782 Phase 2
27 Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer Completed NCT00024076 Phase 2
28 ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma Completed NCT00003989 Phase 2
29 Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064) Completed NCT00831545 Phase 2
30 A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... Completed NCT00923481 Phase 2
31 Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung Completed NCT00005610 Phase 2
32 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2
33 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2
34 Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed NCT01177397 Phase 1, Phase 2
35 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2
36 Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer Completed NCT00002475 Phase 2
37 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2
38 Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver Completed NCT00041808 Phase 1, Phase 2
39 Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma Completed NCT00256282 Phase 2
40 Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma Completed NCT00001832 Phase 2
41 Peptide Vaccination for Patients at High Risk for Recurrent Melanoma Completed NCT00059475 Phase 2
42 131MIBG to Treat Malignant Pheochromocytoma Completed NCT00028106 Phase 2
43 Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases Completed NCT00587964 Phase 2
44 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2
45 RRx-001 in Small, Non-small Cell Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) Recruiting NCT02489903 Phase 2
46 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Recruiting NCT02936323 Phase 1, Phase 2
47 Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. Recruiting NCT02698410 Phase 2
48 A Study of Pembrolizumab in Patients With Neuroendocrine Tumors Recruiting NCT02939651 Phase 2
49 Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Recruiting NCT02575300 Phase 2
50 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Recruiting NCT02259725 Phase 2

Search NIH Clinical Center for Pulmonary Neuroendocrine Tumor

Genetic Tests for Pulmonary Neuroendocrine Tumor

Anatomical Context for Pulmonary Neuroendocrine Tumor

MalaCards organs/tissues related to Pulmonary Neuroendocrine Tumor:

39
Lung, Thyroid, Lymph Node, Fetal Lung

Publications for Pulmonary Neuroendocrine Tumor

Articles related to Pulmonary Neuroendocrine Tumor:

(show all 26)
id Title Authors Year
1
Acromegaly in a patient with a pulmonary neuroendocrine tumor: case report and review of current literature. ( 27349224 )
2016
2
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. ( 26311731 )
2015
3
Cowden Syndrome and Concomitant Pulmonary Neuroendocrine Tumor: A Presentation of Two Cases. ( 26798346 )
2015
4
Carbonic anhydrase II mediates malignant behavior of pulmonary neuroendocrine tumors. ( 25019941 )
2015
5
Co-expression of TTF-1 and neuroendocrine markers in the human fetal lung and pulmonary neuroendocrine tumors. ( 25722034 )
2015
6
Pulmonary neuroendocrine tumor incidentally detected by (18)F-CH PET/CT. ( 23446117 )
2013
7
Promyelocytic leukemia zinc finger and histone H1.5 differentially stain low- and high-grade pulmonary neuroendocrine tumors: a pilot immunohistochemical study. ( 23416030 )
2013
8
A rare case of synchronous bilateral pulmonary neuroendocrine tumor detected by 68Ga-DOTANOC PET/CT. ( 22391733 )
2012
9
Altered expression of microRNA miR-21, miR-155, and let-7a and their roles in pulmonary neuroendocrine tumors. ( 22924844 )
2012
10
Expression of 4F2hc (CD98) in pulmonary neuroendocrine tumors. ( 21750865 )
2011
11
Specific expression of ZO-1 and N-cadherin in rosette structures of various tumors: possible recapitulation of neural tube formation in embryogenesis and utility as a potentially novel immunohistochemical marker of rosette formation in pulmonary neuroendocrine tumors. ( 21785870 )
2011
12
[Expression and clinicopathologic significance of human achaete-scute homolog 1 in pulmonary neuroendocrine tumors]. ( 20677557 )
2010
13
Atypical carcinoid with prominent mucinous stroma: a hitherto unreported variant of pulmonary neuroendocrine tumor. ( 20195926 )
2010
14
Downregulation of drs tumor suppressor gene in highly malignant human pulmonary neuroendocrine tumors. ( 19424611 )
2009
15
Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. ( 18281538 )
2008
16
Immunohistochemical expression of estrogen and progesterone receptors in primary pulmonary neuroendocrine tumors. ( 19061285 )
2008
17
Telomere length, telomerase activity, and expressions of human telomerase mRNA component (hTERC) and human telomerase reverse transcriptase (hTERT) mRNA in pulmonary neuroendocrine tumors. ( 17060405 )
2007
18
Long-term quiescence of ectopic Cushing's syndrome caused by pulmonary neuroendocrine tumor (typical carcinoid) and tumorlets: spontaneous remission or therapeutic effect of bromocriptine? ( 16699304 )
2006
19
Alteration of the E-cadherin/beta-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids. ( 15712207 )
2005
20
Identification of carboxypeptidase E and gamma-glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors by cDNA microarray. ( 15492986 )
2004
21
hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors. ( 14657947 )
2004
22
Divergent cyclin B1 expression and Rb/p16/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors. ( 15154011 )
2004
23
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia as a precursor to pulmonary neuroendocrine tumors. ( 15136447 )
2004
24
Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. ( 9950155 )
1999
25
Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. ( 8623922 )
1996
26
Immunoreactive somatostatin and calcitonin in pulmonary neuroendocrine tumor. ( 2866833 )
1986

Variations for Pulmonary Neuroendocrine Tumor

Expression for Pulmonary Neuroendocrine Tumor

Search GEO for disease gene expression data for Pulmonary Neuroendocrine Tumor.

Pathways for Pulmonary Neuroendocrine Tumor

GO Terms for Pulmonary Neuroendocrine Tumor

Cellular components related to Pulmonary Neuroendocrine Tumor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 terminal bouton GO:0043195 8.8 CALCA GHRH SYP

Biological processes related to Pulmonary Neuroendocrine Tumor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuron migration GO:0001764 9.63 ASCL1 CHL1 NKX2-1
2 axon guidance GO:0007411 9.55 CHL1 NCAM1 NKX2-1 RET SRC
3 forebrain neuron differentiation GO:0021879 9.43 ASCL1 NKX2-1
4 adenohypophysis development GO:0021984 9.4 GHRH SOX2
5 Type II pneumocyte differentiation GO:0060510 9.37 NFIB NKX2-1
6 Clara cell differentiation GO:0060486 9.32 NFIB NKX2-1
7 cerebral cortex GABAergic interneuron differentiation GO:0021892 9.26 ASCL1 NKX2-1
8 glial cell differentiation GO:0010001 9.13 ASCL1 CDH2 NFIB
9 forebrain development GO:0030900 8.92 NFIB NKX2-1 SOX2 SRC

Sources for Pulmonary Neuroendocrine Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....